TCM
CBIO

Tang Capital Management’s Crescent Biopharma CBIO Stock Holding History

Tang Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.3M Buy
1,160,000
+287,602
+33% +$3.3M 1.08% 24
2025
Q4 		$10.3M Buy
872,398
+192,574
+28% +$2.45M 0.51% 39
2025
Q3 		$8.08M Buy
679,824
+629,672
+1,256% +$8.35M 0.31% 71
2025
Q2 		$809K Buy
+50,152
New +$1.06M 0.04% 170

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Tang Capital Management's CBIO Position: Q1 2026 in Review

Tang Capital Management increased its Crescent Biopharma (CBIO) stake by 33% in Q1 2026, buying an estimated $3.3M and bringing the position to 1,160,000 shares worth $21.3M. The position accounts for 1.08% of the portfolio, ranked #24.

Tang Capital Management first reported a position in CBIO in Q2 2025 and has held it in 4 quarters since. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • Tang Capital Management held 1,160,000 shares of Crescent Biopharma worth $21.3M as of Q1 2026.
  • Tang Capital Management bought 287,602 Crescent Biopharma shares in Q1 2026, an estimated $3.3M.
  • Crescent Biopharma made up 1.08% of Tang Capital Management's portfolio in Q1 2026, its #24 holding.
  • Tang Capital Management first reported a position in Crescent Biopharma in Q2 2025 and has held it in 4 quarters since.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on Tang Capital Management's 13F filing for Q1 2026, filed 15 May 2026.